Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT00627588

Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin for the Treatment of Bilateral Idiopathic Parkinson's Disease

A Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin®, Administered Using Stereotactic Injection to the Striatum of Patients With Bilateral, Idiopathic Parkinson's Disease.

Sponsor: Oxford BioMedica

Conditions Parkinson's Disease

Interventions ProSavin

Updated 5 times since 2017 Last updated: May 9, 2013 Started: Jan 31, 2008 Primary completion: Aug 31, 2012 Completion: Aug 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Parkinson's Disease and is currently completed. Oxford BioMedica leads this study, which shows 5 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Oxford BioMedica

Data source: Oxford BioMedica

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cambridge, United Kingdom
• Paris, France